Core Laboratories Inc. /DE/
For the period ended Mar 31, 2025. Filed Apr 28, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed Apr 28, 2025
CLB$9.03+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at March 31, 2025 (Unaudited) and December 31, 2024
CONSOLIDATED BALANCE SHEETS
| March 31,2025 | December 31,2024 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $22,107 | $19,157 |
| Accounts receivable, net of allowance for credit losses of $3,632 and $3,192 at 2025 and 2024, respectively | 117,031 | 111,761 |
| Inventories | 59,031 | 59,402 |
| Prepaid expenses | 10,308 | 10,176 |
| Income taxes receivable | 13,955 | 15,594 |
| Other current assets | 6,336 | 10,516 |
| TOTAL CURRENT ASSETS | 228,768 | 226,606 |
| PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $317,341 and $314,317 at 2025 and 2024, respectively | 97,943 | 97,063 |
| RIGHT OF USE ASSETS | 57,490 | 56,488 |
| INTANGIBLES, net of accumulated amortization and impairment of $19,296 and $19,326 at 2025 and 2024, respectively | 6,279 | 6,403 |
| GOODWILL | 99,445 | 99,445 |
| DEFERRED TAX ASSETS, net | 67,549 | 69,613 |
| OTHER ASSETS | 34,045 | 34,788 |
| TOTAL ASSETS | $591,519 | $590,406 |
| LIABILITIES AND EQUITY | ||
| CURRENT LIABILITIES: | ||
| Accounts payable | $38,497 | $34,549 |
| Accrued payroll and related costs | 24,049 | 22,901 |
| Taxes other than payroll and income | 4,580 | 7,106 |
| Unearned revenues | 9,772 | 9,332 |
| Operating lease liabilities | 11,654 | 10,690 |
| Income taxes payable | 5,459 | 4,851 |
| Other current liabilities | 9,716 | 8,157 |
| TOTAL CURRENT LIABILITIES | 103,727 | 97,586 |
| LONG-TERM DEBT, net | 124,367 | 126,111 |
| LONG-TERM OPERATING LEASE LIABILITIES | 43,981 | 43,343 |
| DEFERRED COMPENSATION | 29,195 | 31,115 |
| DEFERRED TAX LIABILITIES, net | 9,903 | 13,783 |
| OTHER LONG-TERM LIABILITIES | 20,990 | 20,732 |
| COMMITMENTS AND CONTINGENCIES | ||
| EQUITY: | ||
| Preference stock, 6,000,000 shares authorized, $0.01 par value; none issued or outstanding | — | — |
| Common stock, 200,000,000 shares authorized, $0.01 par value, 46,966,868 issued and 46,702,192 outstanding at 2025; 46,966,868 issued and 46,826,820 outstanding at 2024 | 470 | 470 |
| Additional paid-in capital | 113,574 | 109,547 |
| Retained earnings | 149,657 | 150,280 |
| Accumulated other comprehensive income (loss) | (5,886) | (5,769) |
| Treasury stock (at cost), 264,676 and 140,048 shares at 2025 and 2024, respectively | (4,427) | (2,537) |
| Total Core Laboratories Inc. shareholders' equity | 253,388 | 251,991 |
| Non-controlling interest | 5,968 | 5,745 |
| TOTAL EQUITY | 259,356 | 257,736 |
| TOTAL LIABILITIES AND EQUITY | $591,519 | $590,406 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.